Arsenicals
This graph shows the total number of publications written about "Arsenicals" by people in the URMC Research Network by year, and whether "Arsenicals" was a major or minor topic of these publication.
Below are the most recent publications written about "Arsenicals" by people in Profiles.
-
Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Invest. 2011 Aug; 29(7):439-50.
-
Litzow MR, Lee S, Bennett JM, Dewald GW, Gallagher RE, Jain V, Paietta EM, Racevskis J, Rousey SR, Mazza JJ, Tallman MS. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica. 2006 Aug; 91(8):1105-8.
-
Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006 Jun 1; 24(16):2456-64.
-
Jenkins SM, Johnson GV. Microtubule/MAP-affinity regulating kinase (MARK) is activated by phenylarsine oxide in situ and phosphorylates tau within its microtubule-binding domain. J Neurochem. 2000 Apr; 74(4):1463-8.
-
Jenkins SM, Johnson GV. Modulation of tau phosphorylation within its microtubule-binding domain by cellular thiols. J Neurochem. 1999 Nov; 73(5):1843-50.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
